BioCardia Inc. Launches CardiAMP HF II Pivotal Study Enrollment at Henry Ford Health for Ischemic Heart Failure Treatment

Reuters
07-16
<a href="https://laohu8.com/S/BCDA">BioCardia</a> Inc. Launches CardiAMP HF II Pivotal Study Enrollment at Henry Ford Health for Ischemic Heart Failure Treatment

BioCardia, Inc. [Nasdaq: BCDA] has announced the initiation of patient enrollment for its CardiAMP HF II pivotal study at Henry Ford Health in Detroit, Michigan. The study focuses on ischemic heart failure with reduced ejection fraction (HFrEF). This confirmatory trial is designed to evaluate an autologous bone marrow-derived mononuclear cell therapy aimed at promoting microvascular repair, reducing fibrosis, and increasing capillary density in patients with ischemic heart failure. The therapy involves harvesting cells from the patient on the day of the procedure, processing them at the bedside, and delivering them using minimally invasive catheter systems. The procedure concludes with the placement of high doses of the patient's own cells adjacent to damaged zones in the heart. Results from this ongoing trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-022772), on July 16, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10